A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally Administered ADC-1013

Cancer type: Solide tumores

Phase: I

Principal Investigator: Nielsen Dorthe

Country: DK

Keywords: Denmark, Herlev, antibodies, monoclonal, antineoplastic agent, physiological effects of drugs, therapeutic uses, clinical trial, phase I, immunotherapy, active, CD40 Antigen, immunologic factors, injections, intralesional

Status: Completed

Link to